For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Spironolactone | Patients randomized to active therapy with spironolactone spironolactone: aldosterone blocker | 13 | None | 39 | 44 | 44 | 44 | View |
| Placebo | patients randomized to placebo placebo: identical in appearance to spironolactone study drug | 12 | None | 37 | 46 | 46 | 46 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Gynecomastia | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| congestive heart failure | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Prerenal azotemia | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Any gastrointestinal issue | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |